Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia

Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia

•Children treated with blinatumomab for B-ALL with MRD had few side effects and proceeded to hematopoietic cell transplant without delay.•Blinatumomab given prior to transplant reduces MRD and results in favorable leukemia-free survival, toxicity, and overall survival.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood advances 2019-07, Vol.3 (13), p.1926-1929
Hauptverfasser: Keating, Amy K., Gossai, Nathan, Phillips, Christine L., Maloney, Kelly, Campbell, Kristen, Doan, Andrew, Bhojwani, Deepa, Burke, Michael J., Verneris, Michael R.
Format: Artikel
Sprache:eng
Schlagworte:
Stimulus Report
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Children treated with blinatumomab for B-ALL with MRD had few side effects and proceeded to hematopoietic cell transplant without delay.•Blinatumomab given prior to transplant reduces MRD and results in favorable leukemia-free survival, toxicity, and overall survival.
ISSN:2473-9529
2473-9537
DOI:10.1182/bloodadvances.2018025726